Evidence map›Paper›PMID 29914418›Full record

ReviewBMC cancer2018

Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico.

Jacklyn M Nemunaitis, Ursa Brown-Glabeman, Heloisa Soares, Jessica Belmonte, Ben Liem, Itzhak Nir, Victor Phuoc, Rama R Gullapalli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.International journal of molecular sciences · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jacklyn M NemunaitisComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Ursa Brown-GlabemanComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Heloisa SoaresComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Jessica BelmonteComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Ben LiemComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Itzhak NirComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Victor PhuocComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Rama R GullapalliComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA. RGullapalli@salud.unm.edu.ORCID http://orcid.org/0000-0003-4441-1402

Funding

NM-INBRE Sequencing and Bioinformatics CoreP20GM103451 · NIGMS · NEW MEXICO STATE UNIVERSITY LAS CRUCES · PI Charlotte C. Gard · 2012 to 2026
$61.2M
National Institute of General Medical Sciences P20GM103451NIGMS NIH HHS P20 GM103451
6 · The paper itself

Abstract

Gallbladder cancer is a rare malignancy of the biliary tract with a poor prognosis, frequently presenting at an advanced stage. While rare in the United States overall, gallbladder cancer has an elevated incidence in geographically distinct locations of the globe including Chile, North India, Korea, Japan and the state of New Mexico in the United States. People with Native American ancestry have a much elevated incidence of gallbladder cancer compared to Hispanic and non-Hispanic white populations of New Mexico. Gallbladder cancer is also one of the few bi-gendered cancers with an elevated female incidence compared to men. Similar to other gastrointestinal cancers, gallbladder cancer etiology is likely multi-factorial involving a combination of genomic, immunological, and environmental factors. Understanding the interplay of these unique epidemiological factors is crucial in improving the prevention, early detection, and treatment of this lethal disease. Previous studies have failed to identify a distinct genomic mutational profile in gallbladder cancers, however, work to identify promising clinically actionable targets is this form of cancer is ongoing. Examples include, interest in the HER2/Neu signaling pathway and the recognition that chronic inflammation plays a crucial role in gallbladder cancer pathogenesis. In this review, we provide a comprehensive overview of gallbladder cancer epidemiology, risk factors, pathogenesis, and treatment with a specific focus on the rural and Native American populations of New Mexico. We conclude this review by discussing future research directions with the goal of improving clinical outcomes for patients of this lethal malignancy.

Indexed as

FemaleGallbladder NeoplasmsHumansMaleNew MexicoRural PopulationChronic InflammationGallbladder CancerGallstonesHeavy MetalsHER2/NeuNew MexicoPersonalized medicine

Identifiers

PMID29914418
PMCPMC6006713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.